AN ACT RELATING TO HEALTH AND SAFETY -- PRESCRIPTION DRUG SAVINGS AND TRANSPARENCY ACT OF 2026

SB 2563 mandates an independent study by Rhode Island's auditor general to evaluate whether consolidating Medicaid prescription drug management would save costs and improve transparency. The study must compare four models used by other states, including single statewide drug lists (like Connecticut) or direct state contracting (like Kentucky), and assess impacts on state spending, pharmacy rebates, and beneficiary access. It requires full data access from pharmacy benefit managers and related entities - bypassing contractual confidentiality - to ensure the analysis uses complete information on drug expenditures and rebates. This bill directly affects Rhode Island's Medicaid program, which covers children, seniors, people with disabilities, and low-income families, by setting the stage for potential future changes to drug management.